Relationship Between Various Clinical Outcome Assessments in Patients with Blepharospasm
Identifieur interne : 000D24 ( PascalFrancis/Checkpoint ); précédent : 000D23; suivant : 000D25Relationship Between Various Clinical Outcome Assessments in Patients with Blepharospasm
Auteurs : Joseph Jankovic [États-Unis] ; Christopher Kenney [États-Unis] ; Susanne Grafe [Allemagne] ; Roman Goertelmeyer [Allemagne] ; George Comes [Allemagne]Source :
- Movement disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
The objective was to analyze the metric properties of the Jankovic Rating Scale (JRS) and a self-rating patient response outcome scale, the Blepharospasm Disability Index (BSDI(C)), in blepharospasm patients. Data from a randomized, double-blind, active-control clinical trial in 300 patients with blepharospasm treated with either botulinum toxin type A (Botox®) or NT201 (Xeomin®) were used to evaluate the metric properties of the JRS and the BSDI compared with the Patient Evaluation of Global Response (PEGR) and Global Assessment Scale (GAS). The internal consistency of the BSDI was high, Cronbach's Alpha = 0.88, and the retest reliability of the BSDI single items was adequate, Spearman's rank coefficient = 0.453 < r < 0.595. The correlation between JRS sum score and BSDI weighted mean score was r = 0.487 (baseline) and r = 0.737 (control visit), respectively. Using the GAS and PEGR, the results suggest that a change of 2 points in the JRS and of 0.7 points in the BSDI are clinically meaningful. JRS and BSDI are objective indicators of clinical efficacy as suggested by their good validity when compared with physicians' and patients' rating scales. Both, JRS and BSDI, can be used to reliably assess blepharospasm in treatment trials.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0136790Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Relationship Between Various Clinical Outcome Assessments in Patients with Blepharospasm</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Grafe, Susanne" sort="Grafe, Susanne" uniqKey="Grafe S" first="Susanne" last="Grafe">Susanne Grafe</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Merz Phurmaceuticals GmbH, Eckenheimer Landstrasse 100</s1><s2>Frankfurt am Main</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Frankfurt am Main</wicri:noRegion><wicri:noRegion>Eckenheimer Landstrasse 100</wicri:noRegion><wicri:noRegion>Frankfurt am Main</wicri:noRegion></affiliation></author><author><name sortKey="Goertelmeyer, Roman" sort="Goertelmeyer, Roman" uniqKey="Goertelmeyer R" first="Roman" last="Goertelmeyer">Roman Goertelmeyer</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Merz Phurmaceuticals GmbH, Eckenheimer Landstrasse 100</s1><s2>Frankfurt am Main</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Frankfurt am Main</wicri:noRegion><wicri:noRegion>Eckenheimer Landstrasse 100</wicri:noRegion><wicri:noRegion>Frankfurt am Main</wicri:noRegion></affiliation></author><author><name sortKey="Comes, George" sort="Comes, George" uniqKey="Comes G" first="George" last="Comes">George Comes</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Merz Phurmaceuticals GmbH, Eckenheimer Landstrasse 100</s1><s2>Frankfurt am Main</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Frankfurt am Main</wicri:noRegion><wicri:noRegion>Eckenheimer Landstrasse 100</wicri:noRegion><wicri:noRegion>Frankfurt am Main</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0136790</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0136790 INIST</idno><idno type="RBID">Pascal:09-0136790</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F66</idno><idno type="wicri:Area/PascalFrancis/Curation">001D53</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000D24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Relationship Between Various Clinical Outcome Assessments in Patients with Blepharospasm</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Grafe, Susanne" sort="Grafe, Susanne" uniqKey="Grafe S" first="Susanne" last="Grafe">Susanne Grafe</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Merz Phurmaceuticals GmbH, Eckenheimer Landstrasse 100</s1><s2>Frankfurt am Main</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Frankfurt am Main</wicri:noRegion><wicri:noRegion>Eckenheimer Landstrasse 100</wicri:noRegion><wicri:noRegion>Frankfurt am Main</wicri:noRegion></affiliation></author><author><name sortKey="Goertelmeyer, Roman" sort="Goertelmeyer, Roman" uniqKey="Goertelmeyer R" first="Roman" last="Goertelmeyer">Roman Goertelmeyer</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Merz Phurmaceuticals GmbH, Eckenheimer Landstrasse 100</s1><s2>Frankfurt am Main</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Frankfurt am Main</wicri:noRegion><wicri:noRegion>Eckenheimer Landstrasse 100</wicri:noRegion><wicri:noRegion>Frankfurt am Main</wicri:noRegion></affiliation></author><author><name sortKey="Comes, George" sort="Comes, George" uniqKey="Comes G" first="George" last="Comes">George Comes</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Merz Phurmaceuticals GmbH, Eckenheimer Landstrasse 100</s1><s2>Frankfurt am Main</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Frankfurt am Main</wicri:noRegion><wicri:noRegion>Eckenheimer Landstrasse 100</wicri:noRegion><wicri:noRegion>Frankfurt am Main</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blepharospasm</term><term>Bontoxilysin</term><term>Disability</term><term>Evaluation scale</term><term>Human</term><term>Nervous system diseases</term><term>Prognosis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Blépharospasme</term><term>Pathologie du système nerveux</term><term>Pronostic</term><term>Homme</term><term>Bontoxilysin</term><term>Echelle d'évaluation</term><term>Incapacité</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective was to analyze the metric properties of the Jankovic Rating Scale (JRS) and a self-rating patient response outcome scale, the Blepharospasm Disability Index (BSDI(C)), in blepharospasm patients. Data from a randomized, double-blind, active-control clinical trial in 300 patients with blepharospasm treated with either botulinum toxin type A (Botox®) or NT201 (Xeomin®) were used to evaluate the metric properties of the JRS and the BSDI compared with the Patient Evaluation of Global Response (PEGR) and Global Assessment Scale (GAS). The internal consistency of the BSDI was high, Cronbach's Alpha = 0.88, and the retest reliability of the BSDI single items was adequate, Spearman's rank coefficient = 0.453 < r < 0.595. The correlation between JRS sum score and BSDI weighted mean score was r = 0.487 (baseline) and r = 0.737 (control visit), respectively. Using the GAS and PEGR, the results suggest that a change of 2 points in the JRS and of 0.7 points in the BSDI are clinically meaningful. JRS and BSDI are objective indicators of clinical efficacy as suggested by their good validity when compared with physicians' and patients' rating scales. Both, JRS and BSDI, can be used to reliably assess blepharospasm in treatment trials.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>24</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Relationship Between Various Clinical Outcome Assessments in Patients with Blepharospasm</s1></fA08><fA11 i1="01" i2="1"><s1>JANKOVIC (Joseph)</s1></fA11><fA11 i1="02" i2="1"><s1>KENNEY (Christopher)</s1></fA11><fA11 i1="03" i2="1"><s1>GRAFE (Susanne)</s1></fA11><fA11 i1="04" i2="1"><s1>GOERTELMEYER (Roman)</s1></fA11><fA11 i1="05" i2="1"><s1>COMES (George)</s1></fA11><fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA14 i1="02"><s1>Merz Phurmaceuticals GmbH, Eckenheimer Landstrasse 100</s1><s2>Frankfurt am Main</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></fA14><fA20><s1>407-413</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000186999840130</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>34 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0136790</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>The objective was to analyze the metric properties of the Jankovic Rating Scale (JRS) and a self-rating patient response outcome scale, the Blepharospasm Disability Index (BSDI(C)), in blepharospasm patients. Data from a randomized, double-blind, active-control clinical trial in 300 patients with blepharospasm treated with either botulinum toxin type A (Botox®) or NT201 (Xeomin®) were used to evaluate the metric properties of the JRS and the BSDI compared with the Patient Evaluation of Global Response (PEGR) and Global Assessment Scale (GAS). The internal consistency of the BSDI was high, Cronbach's Alpha = 0.88, and the retest reliability of the BSDI single items was adequate, Spearman's rank coefficient = 0.453 < r < 0.595. The correlation between JRS sum score and BSDI weighted mean score was r = 0.487 (baseline) and r = 0.737 (control visit), respectively. Using the GAS and PEGR, the results suggest that a change of 2 points in the JRS and of 0.7 points in the BSDI are clinically meaningful. JRS and BSDI are objective indicators of clinical efficacy as suggested by their good validity when compared with physicians' and patients' rating scales. Both, JRS and BSDI, can be used to reliably assess blepharospasm in treatment trials.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17F</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Blépharospasme</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Blepharospasm</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Blefaroespasmo</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pronostic</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Prognosis</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Pronóstico</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Human</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Bontoxilysin</s0><s2>FE</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Bontoxilysin</s0><s2>FE</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Bontoxilysin</s0><s2>FE</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Echelle d'évaluation</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Evaluation scale</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Escala evaluación</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Incapacité</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Disability</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Incapacidad</s0><s5>13</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de l'oeil</s0><s5>37</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Eye disease</s0><s5>37</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Ojo patología</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de la paupière</s0><s5>38</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Eyelid disease</s0><s5>38</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Párpado patología</s0><s5>38</s5></fC07><fN21><s1>096</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></region><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name></country><country name="Allemagne"><noRegion><name sortKey="Grafe, Susanne" sort="Grafe, Susanne" uniqKey="Grafe S" first="Susanne" last="Grafe">Susanne Grafe</name></noRegion><name sortKey="Comes, George" sort="Comes, George" uniqKey="Comes G" first="George" last="Comes">George Comes</name><name sortKey="Goertelmeyer, Roman" sort="Goertelmeyer, Roman" uniqKey="Goertelmeyer R" first="Roman" last="Goertelmeyer">Roman Goertelmeyer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000D24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:09-0136790
|texte= Relationship Between Various Clinical Outcome Assessments in Patients with Blepharospasm
}}
| This area was generated with Dilib version V0.6.23. |  |